Perspective · 31 May 2022
Conference abstractPublished 15 Aug 2016
Late effects of treatment for childhood cancer
Clinical Hospital Centre Rijeka, Croatia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
During the past decades, significant advances have been made in treatment of pediatric malignancies, with more than 80% of children being cured in most developed countries. Therapy responsible for this survival rate can also produce adverse long-term health-related outcomes, referred to as late effects. Late effects manifest months to years after completion of cancer treatment. It is estimated that 60% of pediatric cancer survivors develop at least one chronic condition and almost 30% experience serious or life-threatening complications during adulthood. The common late effects of childhood cancer encompass several broad domains including growth and development, organ function, reproductive capacity and health of offspring, secondary malignancies, and psychosocial sequelae. Late effects can be anticipated based on therapeutic interventions, but the magnitude of risk and the manifestations in an individual survivor are influenced by numerous factors which are tumor-related, treatment-related and host-related. Any organ system can potentially be affected. Late effects also contribute to an excess risk of premature death among long-term survivors. Relapsed primary cancer remains the most frequent cause of death, followed by cause-specific mortality from subsequent primary neoplasms, and cardiac and pulmonary toxicity. Childhood cancer survivorship is a national public health priority. Long-term follow-up care has taken place in a variety of settings: primary care clinics (pediatrics, internal medicine, family practice), oncology clinics (pediatric and adult), and specialized long-term follow-up clinics. To facilitate survivor and provider access to appropriate follow-up care, compendium of exposure- and risk-based health surveillance recommendations has been developed, including guidelines, health links and comprehensive reviews.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Short communication · 28 Jun 2022
Survey Late poisonous quality of stomach and pelvic radiotherapy for childhood cancer
Short communication · 2021
Potential Late Effects in survivors of childhood cancers.
Research article · 2020
Potential Late Effects in survivors of childhood cancers
Research article · 2 Feb 2018
Bevacizumab (Bmab)+Dihydropyrimidine Dehydrogenase (DPD) Inhibitory Fluoropyrimidine (DIF) Combined Chemotherapy for the Treatment of Late-Stage Elderly Patients with Advanced/Recurent Colorectal Cancer (ARCC)
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectOncology & Cancer
- SubjectPaediatrics & Neonatology
- BylineArticles whose byline prints “Roganovic Jelena”
